Literature DB >> 24436409

Medicine. How thalidomide works against cancer.

A Keith Stewart1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24436409      PMCID： PMC4084783          DOI： 10.1126/science.1249543

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  15 in total

1.  Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation.

Authors:  B Morgan; L Sun; N Avitahl; K Andrikopoulos; T Ikeda; E Gonzales; P Wu; S Neben; K Georgopoulos
Journal:  EMBO J       Date:  1997-04-15       Impact factor: 11.598

2.  Antitumor activity of thalidomide in refractory multiple myeloma.

Authors:  S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

3.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

4.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

5.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

6.  How I treat multiple myeloma in younger patients.

Authors:  A Keith Stewart; Paul G Richardson; Jesus F San-Miguel
Journal:  Blood       Date:  2009-10-27       Impact factor: 22.113

7.  The Ikaros gene is required for the development of all lymphoid lineages.

Authors:  K Georgopoulos; M Bigby; J H Wang; A Molnar; P Wu; S Winandy; A Sharpe
Journal:  Cell       Date:  1994-10-07       Impact factor: 41.582

8.  BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Authors:  Charles G Mullighan; Christopher B Miller; Ina Radtke; Letha A Phillips; James Dalton; Jing Ma; Deborah White; Timothy P Hughes; Michelle M Le Beau; Ching-Hon Pui; Mary V Relling; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2008-04-13       Impact factor: 49.962

9.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

10.  Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity.

Authors:  Marta Cortés; Katia Georgopoulos
Journal:  J Exp Med       Date:  2004-01-12       Impact factor: 14.307
View more
  33 in total

1.  Montelukast inhibits hypoxia inducible factor-1α translation in prostate cancer cells.

Authors:  Caixia Tang; Hu Lei; Jinfu Zhang; Meng Liu; Jin Jin; Hao Luo; Hanzhang Xu; Yingli Wu
Journal:  Cancer Biol Ther       Date:  2018-05-08       Impact factor: 4.742

2.  Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Authors:  Nathan H Fowler; R Eric Davis; Seema Rawal; Loretta Nastoupil; Fredrick B Hagemeister; Peter McLaughlin; Larry W Kwak; Jorge E Romaguera; Michelle A Fanale; Luis E Fayad; Jason R Westin; Jatin Shah; Robert Z Orlowski; Michael Wang; Francesco Turturro; Yasuhiro Oki; Linda C Claret; Lei Feng; Veerabhadran Baladandayuthapani; Tariq Muzzafar; Kenneth Y Tsai; Felipe Samaniego; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

Review 3.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

4.  Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production.

Authors:  David Millrine; Mami Tei; Yohannes Gemechu; Tadamitsu Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

Review 5.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

6.  IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation.

Authors:  Shirong Li; Jing Fu; Hui Wang; Huihui Ma; Xiaoming Xu; Yong-Guang Yang; Shixian Deng; Markus Y Mapara; Suzanne Lentzsch
Journal:  Blood Adv       Date:  2018-03-13

Review 7.  Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.

Authors:  Michal Kuczma; Zhi-Chun Ding; Gang Zhou
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

8.  NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.

Authors:  Dang-Nghiem Vo; Catherine Alexia; Nerea Allende-Vega; Franck Morschhauser; Roch Houot; Cedric Menard; Karin Tarte; Guillaume Cartron; Martin Villalba
Journal:  Oncoimmunology       Date:  2017-12-20       Impact factor: 8.110

9.  Thalidomide inhibits proliferation and epithelial-mesenchymal transition by modulating CD133 expression in pancreatic cancer cells.

Authors:  Congying Chen; Ge Yu; Wenqin Xiao; Miao Xing; Jianbo Ni; Rong Wan; Guoyong Hu
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

Review 10.  Drug repositioning and repurposing for Alzheimer disease.

Authors:  Clive Ballard; Dag Aarsland; Jeffrey Cummings; John O'Brien; Roger Mills; Jose Luis Molinuevo; Tormod Fladby; Gareth Williams; Pat Doherty; Anne Corbett; Janet Sultana
Journal:  Nat Rev Neurol       Date:  2020-09-16       Impact factor: 42.937
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.